论文部分内容阅读
目的:观察曲美他嗪治疗不稳定型心绞痛(UAP)的临床疗效。方法:选择UAP患者78例,随机均分为2组:对照组常规给予硝酸盐制剂、β1-受体阻滞剂或钙拮抗剂、低分子肝素;治疗组在常规治疗的基础上加用曲美他嗪20 mg,tid治疗。结果:治疗组与对照组相比,可改善胸闷、胸痛及乏力症状,能有效缓解心绞痛症状(94.7%:64.1%,P<0.01),心电图缺血性ST-T改善的有效率2组差异有统计学意义(69.2%:48.7%,P <0.05),无明显不良反应发生。结论:传统药物辅以曲美他嗪是治疗UAP的一种安全有效的新方法,可能与改善缺血心肌的能量代谢有关。
Objective: To observe the clinical efficacy of trimetazidine in the treatment of unstable angina pectoris (UAP). Methods: 78 patients with UAP were randomly divided into 2 groups: the control group were given conventional nitrates, β1-blockers or calcium antagonists, low molecular weight heparin; the treatment group was given routine treatment Meizalizin 20 mg, tid treatment. Results: Compared with the control group, the treatment group could improve the symptoms of chest tightness, chest pain and fatigue, effectively relieve the symptoms of angina pectoris (94.7% vs 64.1%, P <0.01), and the effective rate of ischemic ST- There was a statistically significant (69.2%: 48.7%, P <0.05), no significant adverse reactions. Conclusion: Traditional Chinese medicine combined with trimetazidine is a safe and effective new method for the treatment of UAP, which may be related to the improvement of energy metabolism in ischemic myocardium.